Nobel Prize Awarded for Fundamental Discoveries in Molecular Mechanisms of Cellular Vesicle Traffic
|
By LabMedica International staff writers Posted on 14 Oct 2013 |

Image: 2013 Physiology or Medicine Nobel laureate Prof. Randy W. Schekman (Photo by H. Goren, courtesy of the Nobel Foundation; HHMI).

Image: 2013 Physiology or Medicine Nobel laureate Prof. James E. Rothman (Photo courtesy of the Nobel Foundation; Yale University).

Image: 2013 Physiology or Medicine Nobel laureate Prof. Thomas C. Südhof (Photo courtesy of the Nobel Foundation; S. Fisch).
The 2013 Nobel Prize for Physiology or Medicine jointly awarded to scientists James E. Rothman, Randy W. Schekman, and Thomas C. Südhof recognizes the fundamental nature of their discoveries about how the cell organizes one of its major transport systems—about the machinery regulating vesicle traffic and the molecular principles that govern how this cellular cargo is precisely delivered to the right place at the right time.
Through their discoveries, they have revealed this exquisitely controlled system, the disturbance of which has deleterious effects and contributes to various medical disorders, including neurological diseases, diabetes, and immunological disorders. Prof. Schekman, currently at the University of California at Berkeley (USA) and an investigator of Howard Hughes Medical Institute (USA), discovered a set of genes required for vesicle traffic. Prof. Rothman, currently at Yale University (New Haven, CT, USA), unraveled protein machinery that allows vesicle membranes to fuse with their target membranes. Prof. Südhof, currently at Stanford University (CA, USA) and an investigator of Howard Hughes Medical Institute, revealed signals that instruct vesicles to release their cargo with precision.
The cell faces the problem of shipping to the right destination at the right time many types of molecules (including hormones, neurotransmitters, cytokines, and enzymes) to be transported and delivered to other locations in the cell or exported out. How do these vesicles know where and when to deliver their cargo?
Traffic congestion: Prof. Schekman was fascinated by how the cell organizes its transport system and in the 1970s decided to study its genetic basis by using yeast as a model system. In a genetic screen, he identified yeast cells with defective transport machinery, giving rise to vesicles piling up in certain parts of the cell. He found that the cause of this congestion was genetic and went on to identify the mutated genes. He identified three classes of genes that control different facets, thereby providing new insights into this tightly regulated machinery.
Docking: Prof. Rothman was also intrigued by the nature of the cell’s transport system. When studying vesicle transport in mammalian cells in the 1980s and 1990s, he discovered that a protein complex enables vesicles to dock and fuse with their target membranes. During fusion proteins on the vesicle and target membranes bind to each other like a zipper. The fact that there are many such proteins and that they bind only in specific combinations ensures that cargo is delivered to a precise location.
It turned out that some of the genes Prof. Schekman had discovered in yeast coded for proteins corresponding to those Prof. Rothman identified in mammals, revealing an ancient evolutionary origin of this transport system, which operates with the same general principles in yeast and humans. Collectively, they mapped critical components of this machinery.
Timing: Prof. Südhof was interested in how nerve cells communicate with one another in the brain. Synaptic vesicles release neurotransmitters upon nerve cell signaling to its neighbors. How is this controlled so precisely? Calcium ions were known to be involved and in the 1990s Prof. Südhof searched for calcium sensitive proteins in nerve cells. He identified molecular machinery that responds to an influx of calcium ions and directs neighbor proteins rapidly to bind synaptic vesicles to the outer membrane of the nerve cell. The zipper opens up and the contents are released. This explained how temporal precision is achieved and how vesicle contents can be released on command.
Together, these discoveries have had a major impact on our understanding of cellular transport mechanisms.
Related Links:
Nobel Foundation
Through their discoveries, they have revealed this exquisitely controlled system, the disturbance of which has deleterious effects and contributes to various medical disorders, including neurological diseases, diabetes, and immunological disorders. Prof. Schekman, currently at the University of California at Berkeley (USA) and an investigator of Howard Hughes Medical Institute (USA), discovered a set of genes required for vesicle traffic. Prof. Rothman, currently at Yale University (New Haven, CT, USA), unraveled protein machinery that allows vesicle membranes to fuse with their target membranes. Prof. Südhof, currently at Stanford University (CA, USA) and an investigator of Howard Hughes Medical Institute, revealed signals that instruct vesicles to release their cargo with precision.
The cell faces the problem of shipping to the right destination at the right time many types of molecules (including hormones, neurotransmitters, cytokines, and enzymes) to be transported and delivered to other locations in the cell or exported out. How do these vesicles know where and when to deliver their cargo?
Traffic congestion: Prof. Schekman was fascinated by how the cell organizes its transport system and in the 1970s decided to study its genetic basis by using yeast as a model system. In a genetic screen, he identified yeast cells with defective transport machinery, giving rise to vesicles piling up in certain parts of the cell. He found that the cause of this congestion was genetic and went on to identify the mutated genes. He identified three classes of genes that control different facets, thereby providing new insights into this tightly regulated machinery.
Docking: Prof. Rothman was also intrigued by the nature of the cell’s transport system. When studying vesicle transport in mammalian cells in the 1980s and 1990s, he discovered that a protein complex enables vesicles to dock and fuse with their target membranes. During fusion proteins on the vesicle and target membranes bind to each other like a zipper. The fact that there are many such proteins and that they bind only in specific combinations ensures that cargo is delivered to a precise location.
It turned out that some of the genes Prof. Schekman had discovered in yeast coded for proteins corresponding to those Prof. Rothman identified in mammals, revealing an ancient evolutionary origin of this transport system, which operates with the same general principles in yeast and humans. Collectively, they mapped critical components of this machinery.
Timing: Prof. Südhof was interested in how nerve cells communicate with one another in the brain. Synaptic vesicles release neurotransmitters upon nerve cell signaling to its neighbors. How is this controlled so precisely? Calcium ions were known to be involved and in the 1990s Prof. Südhof searched for calcium sensitive proteins in nerve cells. He identified molecular machinery that responds to an influx of calcium ions and directs neighbor proteins rapidly to bind synaptic vesicles to the outer membrane of the nerve cell. The zipper opens up and the contents are released. This explained how temporal precision is achieved and how vesicle contents can be released on command.
Together, these discoveries have had a major impact on our understanding of cellular transport mechanisms.
Related Links:
Nobel Foundation
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







